Global Advocacy with Dr. Anne-Marie Baird | IASLC
Globally, lung cancer is the single most lethal cancer, accounting for 1.8 million deaths last year, yet research funding devoted to lung cancer pales in compar …
Related Articles
Annual Report 2023 | IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and…
IASLC Launches Global Member Survey on Diversity, Equity, and Inclusion – ILCN.org (ILCN/WCLC)
The association seeks input from members to better understand the current DEI landscape so it can continue to build a diverse international community dedicated to…
US Food and Drug Administration Accepts New Drug Application for Ensartinib – ILCN.org (ILCN/WCLC)
The filing was based on results from a global phase III study designed to compare the ALK inhibitor to crizotinib in the first-line treatment of…
The Promise of Artificial Intelligence-Aided Pathology in Thoracic Oncology – ILCN.org (ILCN/WCLC)
Profs. Jan von der Thüsen and John Le Quesne say while still in the early phases, AI has the potential to bring accessible and affordable…
Antibody Drug Conjugates: Diamonds in the Rough? – ILCN.org (ILCN/WCLC)
Drs. Matthew Lee, Benjamin Levy, and Balazs Halmos say several key issues need to be addressed before this class of agents can achieve wider impact.
IASLC DEI Initiative Global Member Survey | IASLC
As part of the IASLC’s 2024 DEI Initiative, the association is gathering member insights through an online survey and a series of virtual focus groups…
IASLC’s Diversity, Equity and Inclusion (DEI) Survey
This survey is intended to better understand your membership experience at IASLC as it relates to diversity, equity, inclusion, and accessibility. We want to explore…
Antibody Drug Conjugates: Diamonds in the Rough? – ILCN.org (ILCN/WCLC)
Drs. Matthew Lee, Benjamin Levy, and Balazs Halmos say several key issues need to be addressed before this class of agents can achieve wider impact.
FLAURA 2 Post-progression Outcomes Demonstrate Consistent Benefit, Favor Combination Arm – ILCN.org (ILCN/WCLC)
During the European Lung Cancer Congress, Dr. Natalia Valdiviezo presented the data, which favored frontline osimertinib plus chemotherapy compared to osimertinib alone for patients with…
ESMO 2023 Highlights: Early-Stage NSCLC, SCLC, Thymic Carcinoma | IASLC
Part 2 of our podcast coverage on ESMO 2023 includes an in-depth interview with Dr. Jarushka Naidoo on early-stage NSCLC, including updates from CHECKMATE 816,…